Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by Leerink Swann

Leerink Swann reissued their buy rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note issued to investors on Tuesday morning, TipRanks reports.

A number of other equities research analysts have also issued reports on the stock. ValuEngine lowered shares of Intra-Cellular Therapies from a buy rating to a hold rating in a research note on Wednesday, September 4th. Cantor Fitzgerald set a $27.00 target price on shares of Intra-Cellular Therapies and gave the company a buy rating in a research note on Tuesday. Royal Bank of Canada set a $26.00 target price on shares of Intra-Cellular Therapies and gave the company a buy rating in a research note on Wednesday, August 7th. Jefferies Financial Group began coverage on shares of Intra-Cellular Therapies in a research note on Monday, August 12th. They issued a buy rating and a $16.00 target price on the stock. Finally, Cowen restated a buy rating and issued a $28.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, July 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. Intra-Cellular Therapies currently has a consensus rating of Buy and an average price target of $23.63.

Shares of Intra-Cellular Therapies stock traded down $0.86 during trading on Tuesday, reaching $9.60. The company had a trading volume of 10,125 shares, compared to its average volume of 698,343. The company has a market cap of $573.80 million, a price-to-earnings ratio of -3.50 and a beta of 1.19. The firm’s fifty day moving average is $8.84 and its 200-day moving average is $11.76. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.86 and a current ratio of 8.86. Intra-Cellular Therapies has a fifty-two week low of $7.41 and a fifty-two week high of $23.62.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.15. On average, research analysts anticipate that Intra-Cellular Therapies will post -3.39 EPS for the current fiscal year.

In other Intra-Cellular Therapies news, Director Christopher D. Alafi acquired 125,000 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were purchased at an average price of $8.52 per share, for a total transaction of $1,065,000.00. Following the completion of the purchase, the director now directly owns 341,223 shares in the company, valued at $2,907,219.96. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher D. Alafi acquired 485,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average price of $10.26 per share, for a total transaction of $4,976,100.00. Following the purchase, the director now owns 341,223 shares of the company’s stock, valued at $3,500,947.98. The disclosure for this purchase can be found here. 18.20% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ITCI. Quantamental Technologies LLC bought a new position in Intra-Cellular Therapies in the 2nd quarter worth about $49,000. Bank of Montreal Can grew its position in Intra-Cellular Therapies by 114.4% in the 2nd quarter. Bank of Montreal Can now owns 7,067 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 3,771 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Intra-Cellular Therapies by 883.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,361 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 9,307 shares during the last quarter. First Mercantile Trust Co. grew its position in Intra-Cellular Therapies by 12.3% in the 1st quarter. First Mercantile Trust Co. now owns 11,522 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 1,265 shares during the last quarter. Finally, Slow Capital Inc. bought a new position in Intra-Cellular Therapies in the 2nd quarter worth about $195,000. Hedge funds and other institutional investors own 68.97% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

See Also: P/E Growth (PEG)

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.